Pneumococcal vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Rheumatic DiseasePneumococcal DiseaseAutoimmune Rheumatic Diseases

63 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

1

Voltaren

Novartis

Approved

—2

Advil

KKenvue Brands

Approved

—3

Decadron

AAspen Global Incorporated

Approved

—4

Oruvail

WWyeth-Lederle Vaccines

Approved

—5

MS Contin

HHikma Pharmaceuticals LLC

Approved

—6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—7

Ansaid

PPharmacia and Upjohn

Approved

—8

Bextra

TThe Searle Company Limited Pakistan

Approved

—9

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—10

Zovirax

BBp Consulting, Inc

Approved

—Show 48 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity13 trials

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Completed·GSK·Phase 2·NCT00338351·240 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00344318·806 enrolled

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

Completed·GSK·Phase 2·NCT01262872·1,320 enrolled

Show 10 more trials

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

Completed·GSK·Phase 3·NCT00390910·286 enrolled

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Completed·GSK·Phase 3·NCT01119625·238 enrolled

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

Completed·GSK·Phase 2·NCT01204658·576 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers

Completed·GSK·Phase 1·NCT01485406·61 enrolled

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Completed·GSK·Phase 2·NCT01616459·953 enrolled

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination

Completed·GSK·Phase 2·NCT00985751·257 enrolled

Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00307541·120 enrolled

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Completed·Novartis·Phase 2·NCT00721396·1,885 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Completed·GSK·Phase 3·NCT00334334·1,572 enrolled

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Completed·Sanofi·Phase 3·NCT03547271·1,660 enrolled

Vaccination9 trials

Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™

Completed·GSK·Phase 3·NCT00907777·52 enrolled

Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™

Completed·GSK·Phase 3·NCT00680914·503 enrolled

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Completed·GSK·Phase 3·NCT00808444·466 enrolled

Show 6 more trials

Booster and Catch-up Vaccination With Vaccine GSK1024850A

Completed·GSK·Phase 3·NCT01030822·282 enrolled

Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A

Completed·GSK·Phase 3·NCT00792909·172 enrolled

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Completed·GSK·Phase 3·NCT00891176·582 enrolled

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

Completed·GSK·Phase 3·NCT00814710·360 enrolled

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children

Completed·GSK·Phase 3·NCT01027845·360 enrolled

Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.

Completed·GSK·Phase 3·NCT00829010·489 enrolled

Vaccine8 trials

A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study

Completed·GSK·Phase 3·NCT00307554·1,600 enrolled

Evaluation of Pneumococcal Vaccine Formulations in Young Adults

Completed·GSK·Phase 1·NCT00707798·157 enrolled

Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration

Completed·GSK·Phase 3·NCT00758264·363 enrolled

Show 5 more trials

Evaluation of Pneumococcal Vaccine Formulations in Elderly

Completed·GSK·Phase 1·NCT00756067·168 enrolled

Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

Completed·GSK·Phase 2·NCT00896064·43 enrolled

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Completed·Sanofi·Phase 3·NCT01411241·720 enrolled

PPV: Pneumococcal Polysaccharide Vaccine in Older Adults

Completed·NNational Institute on Aging (NIA)·Phase 4·NCT00239694·100 enrolled

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

Completed·Sanofi·Phase 1·NCT01444001·63 enrolled

Memory3 trials

Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)

Completed·GSK·Phase 3·NCT00169507·100 enrolled

Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.

Completed·GSK·Phase 3·NCT00333450·120 enrolled

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

Completed·GSK·Phase 2·NCT00307567·689 enrolled

Children2 trials

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Completed·GSK·Phase 3·NCT00463437·1,437 enrolled

A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 2·NCT00169481·689 enrolled

16 more indications

Immunization2 trials

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria

Completed·GSK·Phase 3·NCT01153893·105 enrolled

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali

Completed·GSK·Phase 3·NCT00985465·218 enrolled

Acute otitis media2 trials

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00466947·23,802 enrolled

Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A

Completed·GSK·Phase 3·NCT00839254·6,181 enrolled

Infections2 trials

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Completed·GSK·Phase 2·NCT01545375·1,806 enrolled

A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in Africa

Completed·GSK·Phase 2·NCT06213506·180 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

Completed·GSK·Phase 2·NCT00307528·146 enrolled

Effectiveness1 trial

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease

Completed·GSK·Phase 3·NCT00861380·41,188 enrolled

Long-term Follow-up1 trial

Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children

Completed·GSK·Phase 3·NCT00950833·466 enrolled

Treatment1 trial

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Completed·GSK·Phase 3·NCT00496015·750 enrolled

COPD1 trial

Structured Review: To Optimise Management and Prevent Harm in COPD

Not yet recruiting·NNorthumbria Healthcare NHS Foundation Trust·N/A·NCT07460154·96 enrolled

Immune Response1 trial

Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.

Completed·GSK·Phase 2·NCT00327522·10 enrolled

COVID-191 trial

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Completed·CCureVac·Phase 2·NCT04515147·668 enrolled

Immune System1 trial

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01339000·1 enrolled

Aspiration1 trial

Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity

Unknown status·LLeiden University Medical Center·N/A·NCT06202703·5 enrolled

Rheumatic Disease1 trial

Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases

Recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT07252791·114 enrolled

Chronic Lymphocytic Leukemia1 trial

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00323557·39 enrolled

Pneumococcal Disease1 trial

Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes

Recruiting·UUniversity of Alabama at Birmingham·Approved·NCT07135453·70 enrolled

Autoimmune Rheumatic Diseases1 trial

Effect of Methotrexate Discontinuation on Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Patients With Autoimmune Rheumatic Diseases

Recruiting·UUniversity of Sao Paulo General Hospital·Approved·NCT07242092·192 enrolled

Details

Drug Info

Related News